Protocols
22 protocol(s) meet the specified criteria
Disease Site: Bones and Joints
Protocol No.TitleStatus
10-CBAA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indicationsOpen
15-MMUDA Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic MalignanciesOpen
201312100A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell TransplantOpen
A-TREATAmerican Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT) Open
A051301 A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo In Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Of The Activated B-Cell Subtype Open
AEWS1031A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing SarcomaOpen
AEWS1221Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing SarcomaOpen
AOST1321Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory OsteosarcomaOpen
BMT-CTN-1301A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host DiseaseOpen
EBV-CTL-301Multicenter, Open-Label, Phase 3 Trial of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Allogeneic Hematopoietic Cell Transplant (alloHCT) Patients with EBV-Associated Post-Transplant Lymphoproliferative Disease (EBV-PTLD) after Failure of RituximabOpen
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
LCCC1511Skin Tissue Banking ProtocolOpen
LCCC1530AFitness in Allogeneic Stem Cell Transplantation (FAST) Sub-StudyOpen
LCCC1602Health services use and social outcomes of adult survivors of childhood cancerOpen
LCCC1704Assessing the Feasibility of Screening and Treating Anxiety and Depression in the Bone Marrow Transplant PopulationOpen
LCCC1734Adaptation of the Parenting Concerns Questionnaire for Patients with IllnessOpen
MDT16075OsteoCool Tumor Ablation Post-Market Study (OPuS One)Open
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NC-6300-001A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue SarcomaOpen
NG-BSP-600-001Evaluation of the CytoRADx System as a Biodosimeter with Human Subjects Receiving Radiation TherapyOpen
PCYC-1140-IMA Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)Open
VEG116731A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid TumorsOpen